-transparent.png){kind=logo}
We treated 29 rheumatoid arthritis patients with levamisole. on the basis of a 25% improvement in any 3 of 6 measurements 95% of the patients had a favourable response within 20 weeks. However, 64% of the patients discontinued levamisole by 40 to 60 weeks because of rash or secondary treatment failures. Delayed skin reactivity to streptokinase-streptodornase increased significantly in the entire treatment group, but there was in inverse correlation between skin test enhancement and clinical response. There was no overall change in lymphocytes response to phytohaemagglutinin (PHA) after 4 and 16 weeks of treatment, but seven patients with enhanced lymphocyte responsiveness to PHA experienced an earlier clinical response to levamisole. Treatment with levamisole frequently results in clinical improvement in rheumatoid arthritis, but this is not clearly related to a stimulatory effect on cell-mediated immunity. Its long-term usefulness may be limited by a high incidence of relapse and rash.
L A Runge, and
R S Pinals, and
R H Tomar
January 1981,
Scandinavian journal of rheumatology,
L A Runge, and
R S Pinals, and
R H Tomar
October 1977,
La Nouvelle presse medicale,
L A Runge, and
R S Pinals, and
R H Tomar
January 1981,
European journal of rheumatology and inflammation,
L A Runge, and
R S Pinals, and
R H Tomar
March 1977,
Revue du rhumatisme et des maladies osteo-articulaires,
L A Runge, and
R S Pinals, and
R H Tomar
January 1980,
Agents and actions. Supplements,
L A Runge, and
R S Pinals, and
R H Tomar
July 1982,
La Clinica terapeutica,
L A Runge, and
R S Pinals, and
R H Tomar
June 1976,
Revue du rhumatisme et des maladies osteo-articulaires,
L A Runge, and
R S Pinals, and
R H Tomar
October 1978,
La Nouvelle presse medicale,
L A Runge, and
R S Pinals, and
R H Tomar
May 1977,
La Nouvelle presse medicale,
L A Runge, and
R S Pinals, and
R H Tomar
August 1986,
Ryumachi. [Rheumatism],
